Review Article

Key Factor Regulating Inflammatory Microenvironment, Metastasis, and Resistance in Breast Cancer: Interleukin-1 Signaling

Fengjie Liu,1 Lihong Li,1 Meng Lan,1 Tengteng Zou,1 Zhaodi Kong,1 Tiange Cai,2 Xiao Yu Wu,3 and Yu Cai1,4

1College of Pharmacy, Jinan University, Guangzhou 510632, China
2College of Life Sciences, Liaoning University, Shenyang 110036, China
3Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada M5S 3M2
4Guangdong Key Lab of Traditional Chinese Medicine Information Technology, Guangzhou 510632, China

Correspondence should be addressed to Tiange Cai; caitiange@163.com, Xiao Yu Wu; sxy.wu@utoronto.ca, and Yu Cai; caiyu8@sohu.com

Fengjie Liu, Lihong Li, and Meng Lan contributed equally to this work.

Received 23 June 2021; Accepted 20 August 2021; Published 24 September 2021

Academic Editor: Matilde Otero-Losada

Breast cancer is one of the top-ranked cancers for incidence and mortality worldwide. The biggest challenges in breast cancer treatment are metastasis and drug resistance, for which work on molecular evaluation, mechanism studies, and screening of therapeutic targets is ongoing. Factors that lead to inflammatory infiltration and immune system suppression in the tumor microenvironment are potential therapeutic targets. Interleukin-1 is known as a proinflammatory and immunostimulatory cytokine, which plays important roles in inflammatory diseases. Recent studies have shown that interleukin-1 cytokines drive the formation and maintenance of an inflammatory/immunosuppressive microenvironment through complex intercellular signal crosstalk and tight intracellular signal transduction, which were found to be potentially involved in the mechanism of metastasis and drug resistance of breast cancer. Some preclinical and clinical treatments or interventions to block the interleukin-1/interleukin-1 receptor system and its up- and downstream signaling cascades have also been proven effective. This study provides an overview of IL-1-mediated signal communication in breast cancer and discusses the potential of IL-1 as a therapeutic target especially for metastatic breast cancer and combination therapy and current problems, aiming at enlightening new ideas in the study of inflammatory cytokines and immune networks in the tumor microenvironment.

1. Introduction

The history of interleukin-1 (IL-1) dates back to the early 1940s, from the identification of the fever-inducing activity of “soluble factors” produced by endotoxin-stimulated leukocytes, to the discovery of inflamasomes and clinical benefits of anti-IL-1β therapy, encompassing the entire field of inflammatory cytokines, Toll-like receptors (TLRs), and innate immune responses [1]. IL-1 includes two agonists, IL-1α and IL-1β, which trigger signals via binding to IL-1 receptor 1 (IL-1R1) and recruitment of an accessory peptide chain [2]. The reason for having two IL-1 agonists may lie in the difference in robustness or specific functions between them [3]. Subsequently, the IL-1 receptor antagonist (IL-1Ra) was discovered, which specifically blocks IL-1R1 [4]. IL-1, together with several other sequentially discovered structurally related members, constitutes the IL-1 family. To date, there are 11 members of the IL-1 family [5]. These cytokines have pleiotropic functions, including regulating innate and adaptive immune responses; participating in the physiological regulation of homeostatic processes and host defense against pathogens, injury, and environmental
stresses; and directly affecting transcription of mRNA [6, 7]. Antagonists in the IL-1 family cytokines and inhibitors in the IL-1 receptor family that function as membrane-bound or soluble decoy receptors have an important role in the biological activity of IL-1 and the negative regulation of inflammation induced by IL-1 [8].

IL-1 is a proinflammatory cytokine that affects cellular and organ inflammatory reactions, immune responses, and homeostatic regulation at low concentrations, and has long been known to be important in oncogenesis, invasion, metastasis, and tumor host interactions [9, 10]. IL-1 blockers applied to some autoimmune and inflammatory diseases are currently being tested in preclinical and human clinical experiments for tumor therapy [11]. The role and regulatory mechanisms of IL-1 signaling has been extensively studied in a variety of infectious diseases, inflammation, and inflammation-related cancers, such as colon cancer, liver cancer, gastric cancer, cervical carcinoma, and lymphoma, but is still not well understood in breast cancer (BC) [12–14]. Although BC has not been recognized as an inflammation-related cancer except inflammatory breast cancer (IBC) [15], it is well known that inflammation is a fundamental feature of the tumor microenvironment (TME) [16]. TME infiltrated a large number of immune and inflammatory mediators, including abundant IL-1 cytokines derived from immune or tumor cells. These mediators were thought to be key regulators of TME [17, 18]. Studies in recent years have also confirmed the important role of IL-1 in the BC microenvironment. However, the role of IL-1 signaling in the BC microenvironment is controversial, despite most studies showing its tumor promoting effects [19]. The dual functions in tumorigenesis, both pro- and antitumorigenic, largely depend on the source of the cytokines, levels present in TME, tissues and organs involved, inflammatory context, and stage of the cancer [20].

No matter which subtype of BC, it shows different degrees of inflammatory status in cancer progression, which is a common denominator, and thus can provide a generally applicable therapeutic idea. Whether IL-1 is the originator of the protumor inflammatory microenvironment in BC remains unclear. Questions on the regulatory mechanisms of IL-1 signaling: the crosstalk network between different cells and between different intracellular signal transduction channels, by which IL-1 signaling and its regulation affect aspects of inflammation, immunity, metastasis, and drug resistance in BC microenvironment; and the usability of IL-1 signaling blockade in terms of clinical treatment in BC may lead us to discover a novel biomarker or effective therapeutic target.

2. Breast Cancer and Targeted Therapy

In the last decade, the global incidence of BC has shown an increasing trend with no significant reduction in mortality [21, 22]. Patients with early, locally advanced, and locally recurrent BC are considered to have a higher chance of cure. But nearly 12% of patients diagnosed with BC will eventually develop into metastatic disease, which received palliative treatment only trying to relieve symptoms, prolong survival, and maintain quality of life [23–25].

Systematic treatment of patients with nonmetastatic BC is determined by subtypes: hormone receptor-positive (HR+) patients receive endocrine therapy, and a few of them receive chemotherapy at the same time; human epidermal growth factor receptor 2-positive (HER2+) patients receive HER2-targeted antibody or small molecule inhibitor combined chemotherapy; due to the high heterogeneity, invasiveness, and lack of treatment options, chemotherapy is still the standard treatment for triple negative breast cancer (TNBC). Local treatment of nonmetastatic BC includes surgical resection and postoperative radiotherapy [26, 27]. In recent years, the progress of chemotherapy, endocrine therapy, immunotherapy, new targeted therapy, and combination therapy has significantly improved the clinical outcomes and prognosis of BC, and made the prospect of long-term disease control of metastatic BC more and more realistic [28–31]. However, acquired tumor resistance is the major reason limiting the treatment effect [32]. Therefore, great efforts have been devoted in recent years to evaluate the molecular characteristics of metastasis and elucidate the mechanisms of drug resistance in BC in order to find novel molecular targets and therapeutic strategies [33–35].

Targeted therapies locate and inhibit tumor-related pathways, such as phosphoinositide 3-kinase (PI3K)/V-akt murine thymus viral oncogene homolog (AKT)/mammalian/mechanistic target of rapamycin (mTOR), rapidly accelerated fibrosarcoma (RAF), mitogen-activated protein kinase (MAPK), histone deacetylase (HDAC), cyclin-dependent kinases (CDK), and poly(ADP-ribose) polymerase (PARP), by molecules binding to extracellular receptors, such as trastuzumab against HER2 and bevacizumab against vascular endothelial growth factor (VEGF), or by cytoplasmic blocking of small molecules, which is mainly aimed at the tumor [36–38]. Targeted therapies hold good promise in cancer treatment. But targeted therapies for BC face the challenges of diminishing returns, increasing costs of cancer care, and risk of overtreatment [39]. TME is associated with proliferation, angiogenesis, metastasis, apoptosis inhibition, immune system suppression, and drug resistance in BC [40]. Due to the recognition that the cancer stroma is the protagonist of cancer progression and the fact that TME is much more genetically stable than cancer, the development of dual anticancer strategies that target both cancer cells and TME will undoubtedly become the focus of current and future research, which may also be the key to the treatment success of BC with genetic and phenotypic heterogeneity [41].

3. Breast Cancer Microenvironment

In addition to tumor cells, the BC microenvironment also contains a large number of other distinct cell types collectively referred to as stromal cells, including vascular endothelial cells (VECs), cancer-associated fibroblasts (CAF), mesenchymal stem cells (MSCs), and immune cells such as tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), T lymphocytes, B lymphocytes, as well as myoepithelial cells and adipocytes. Besides, several noncellular components, including extracellular matrix (ECM), exosomes, soluble cytokines or signaling molecules,
and occasionally the blood and lymphatic vascular network, have been identified. The physical characteristics of TME, such as hypoxia, acidity, inflammation, and high interstitial fluid pressure, also differ from those of normal tissues [42]. TME is now recognized as a hallmark of cancer biology. Infiltration of TAMs, tumor-associated neutrophils (TANs), MDSCs, T regulatory cells (Tregs), T helper IL-17-producing cells (Th17s), metastasis-associated macrophages (MAMs), and CAFs enables immune escape, tumor growth, angiogenesis, metastasis, and treatment resistance in multiple tumors, including BC [43–45]. Moreover, the ECM, ECM proteins, chemokines, cytokines, growth factors, and the physical state of TME can all influence the behavior and treatment response of solid tumor in complex ways and predict clinical outcomes [35, 46, 47].

The relevance of inflammation to cancer has been demonstrated. Normally, proinflammatory and anti-inflammatory signals are maintained in a state of balance called inflammatory homeostasis (central). However, dysregulation and prolonged maintenance of inflammation lead to chronic inflammation or immunosuppression and may contribute to the development of several diseases, including cancer [48]. Tumor itself and tumor-triggered inflammation can also promote malignant progression and cause immunosuppression through the recruitment and activation of inflammatory cells [49]. Complement system and kinins, vasoactive amines, cytokines, and hormones are considered important inflammatory mediators in the BC microenvironment [50]. Various overexpressed inflammatory mediators exert their biological effects locally or at a distance through the systemic circulation to influence progression, metastasis, and treatment outcome of BC by establishing a supportive immune or inflammatory microenvironment [51]. Compared with other cancers, the role of the immune and inflammatory systems in the development of human BC remains poorly understood. As the prototypical inflammatory cytokine upstream of the cytokine cascade, the role of IL-1 in tumor initiation and progression and tumor-associated inflammation is of sufficient interest [10]. The availability of IL-1R1 conditional demolded mouse models has made it possible to dissect the role of IL-1/IL-1R1 signaling in different cell types in TME [18].

4. IL-1 Single-Nucleotide Polymorphisms and Breast Cancer Risk

Genetic variation is an important inducer of cancer, and single-nucleotide polymorphisms (SNPs) are one of the most common heritable variations in the human genome. There has been an attempt to explore the association between IL-1 SNPs and cancer risk. 144 different SNPs have been described in the IL-1β gene [52]. At base pairs in these transcription sites, base transitions between C and T have been widely reported [53, 54]. Recent studies have shown that IL-1β SNPs rs1143634, rs1143627, rs1143623, and rs10490571 were suggested to be associated with BC risk, while the results of the association of rs16944 with BC risk were inconsistent [55–62]. More studies on IL-1 SNPs and their functions affecting the balance of IL-1 protein may help to identify patients at risk and the severity of the disease and may provide additional therapeutic options in some groups of patients.

5. IL-1 Signaling

IL-1 signaling under the title of the article refers to intercellular crosstalk and intracellular signal transduction driven by the IL-1α/β-IL-1R system. IL-1 is derived from dendritic cells (DCs), monocytes, macrophages, mast cells, neutrophils, B cells, T cells, endothelial cells, epithelial cells, dying cells, and tumor cells [5]. As the initial member of the IL-1 family, IL-1 has been recognized as a key immune and inflammatory mediator with important roles in tumorigenesis, invasion, metastasis, and tumor host interactions by mediating chronic inflammation, tumor angiogenesis, activation of the IL-17 pathway, induction of MDSCs, recruitment of macrophages, and skewing and suppression of antitumor immunity [9, 10].

The potent proinflammatory effects of IL-1 follow three major steps: cellular expression, membrane receptor binding, and intracellular signal transduction. IL-1α and IL-1β are translated into 31 kDa precursor forms (pro-IL-1α and pro-IL-1β), cleavage of which generates 17 kDa mature forms (IL-1α and IL-1β). Unlike pro-IL-1β, pro-IL-1α has a functional nuclear localization signal in the N-terminal domain [63, 64]. Thus, both forms of IL-1α are biologically active and have dual functions, i.e., binding to IL-1R1 to exert damage-associated molecular patterns (DAMPs) or “alarming” function, or directly regulating transcription of genes [20, 65]. It was found that HS-1-associated protein X (HAX) 1, a protein associated with mitochondria, endoplasmic reticulum, and nuclear membrane, can bind to pro-IL-1α and promote its nuclear localization. Pro-IL-1α interacts with histone acetyltransferases P300, p300/CBP-associated factor (PCAF), and general control nonrepressible 5 (GCN5) in the nucleus and regulates gene expression independently of IL-1R. Pro-IL-1α is also posttranslationally modified, including myristoylation at Lys82, phosphorylation at Ser90, and glycosylation at D64. Myristoylation and glycosylation are associated with the membrane-bound form of IL-1α. But the functions of these modifications are largely unknown [63]. The production of IL-1α requires intracellular or extracellular proteases (calpain II, caspase-1, chymotrypsin, elastase, and granzyme B) [63, 64]. The necessity of this proteolytic cleavage may manifest in the enhanced biological potency of pro-IL-1α cleaved by inflammatory proteases [66]. IL-1α is constitutively expressed in epithelial, endothelial, and stromal cells and can be upregulated in hematopoietic and nonhematopoietic cells by a variety of stimuli, including Toll-like receptor (TLR) agonists, inflammatory cytokines, oxidative stress, fatty acid-induced mitochondrial uncoupling, and hormones [63]. IL-1α promoter lacks typical TATA and CAAT box regulatory regions but contains binding sites for activator protein-1 (AP1) and nuclear factor kappa B (NF-κB) transcription factors, which are upregulated during inflammatory stimulation [63].
As a key proinflammatory cytokine, IL-1β is mainly expressed in innate immune cells [18]. Different from IL-1α, IL-1β is only active as a mature, secreted molecule, with tightly regulated processes of production and secretion. IL-1β requires a "dual signal" process to become activated. Signal 1 events represent the transcription and translation of pro-IL-β induced through activation of TLR, tumor necrosis factor (TNF), IL-1R, AP1, or NF-kB. Signal 2 is an activation step dependent on the inflammasome complex, which consists of a sensing molecule NOD-like receptor (NLR/AIM2-like receptor (ALR), an adaptor molecule apoptosis-associated speck-like protein (ASC), and an activation and recruitment domain of the caspase. The inflammasome platform recruits and activates caspase-1/11, which cleaves the N-terminal 116 amino acids of the pro-IL-1β polypeptide to convert it into mature IL-1β [63, 67–71]. NLR protein families mostly have a variable N-terminal domain and a C-terminal leucine-rich repeat (LRR) domain. This family is further divided into NLRP or NLRC receptors based on the presence of an N-terminal pyrin domain (PYD) or caspase activation and recruitment domain (CARD). Among them, NLRP1 (NOD-like receptor family PYD domain-containing protein 1), NLRP3, and NLRC4 (NOD-like receptor family CARD-containing protein 4) are able to induce the formation of an inflammasome, serving as platforms for activating caspase-1 [72]. However, inflammasome-independent processing of IL-1β has also been demonstrated in caspase-11-deficient mice, and neutrophil proteases including elastase, proteinase-3, granzyme A, and cathepsin G are able to extracellularly convert pro-IL-1β into active mature protein [65]. Since IL-1α and IL-1β lack a signal peptide, they are not secreted via the conventional endoplasmic reticulum/Golgi pathway but via an unconventional protein secretion pathway [73]. This mode of secretion may involve exocytosis of secretory lysosomes, cytolyis, multivesicular body formation, microvesicle shedding, and direct efflux during hypertonic cell death, and cleavage of IL-1β is thought to be necessary for this mode [65, 67].

The IL-1 receptor family comprises 10 members, simply named IL-1R1–IL-1R10 [65]. The extracellular Ig domains of the receptors share the structure with the intracellular Toll-like/IL-1R (TIR) domain [8]. IL-1α and IL-1β bind to the extracellular Ig domain of IL-1R1. Ligand-induced conformational changes recruit the nonbinding accessory chain IL-1RaCP to form a heterotrimeric complex [8]. The trimeric IL-1R complex recruits myeloid differentiation primary response gene 88 (MyD88) via its C-terminal TIR domains. MyD88 oligomerizes via its death domain (DD) and TIR domain, and it interacts with interleukin-1 receptor-associated kinase 4 (IRAK4) to form the mydosome complex, which serves as a platform to phosphorylate IRAK4, IRAK2, and IRAK1. Alterations in the recruitment and oligomerization of TNF receptor-associated factor 6 (TRAF6) and other signaling intermediates then occur, which participate in the activation of NF-κB, MAPK, p38, Janus kinase, extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) to initiate the transcription of inflammatory cytokines [5, 71, 74]. The synthesis, secretion, activated signal transduction, and subsequent role of IL-1 signaling are shown in Figure 1. The targeted genes of IL-1 include IL-1α and IL-1β themselves, as well as other inflammatory factors such as IL-6, IL-8, monocyte chemotactic protein 1 (MCP-1)/C-C chemokine ligand 2 (CCL2), and cyclooxygenase-2 (COX-2) [68, 75, 76]. IL-1R1 can also bind to IL-1Ra, which does not produce a signal due to its lack of an IL-1 receptor accessory protein interaction domain, thereby acting as a competitive binding factor to inhibit proinflammatory signaling [66]. IL-1R2 is a membrane-bound or released form of a decoy receptor with an extracellular region similar to that of IL-1R1. But it has a short cytoplasmic domain unable to generate a signal, acting as a molecular trap to block signal generation [5, 10, 77]. IL-1R2 is the key negative regulator of the IL-1 signaling, acting intracellularly, on the cell surface, and extracellularly to inhibit maturation of IL-1α/β, sequester their active form, or hinder the assembly of signaling complexes [77]. Soluble receptors (sIL-1R1, sIL-1R2, and sIL-1RaP) present in the circulation can also sequester IL-1 and reduce signal production [78].

6. Role of IL-1 Signaling in Breast Cancer Microenvironment

As shown in Figures 2 and 3, there is a complex intercellular and intracellular crosstalk mediated by IL-1 signaling in the breast cancer microenvironment, which may contribute to its role in tumor-associated inflammation, immunosuppression during tumor development, metastasis leading to recurrence, and acquired drug resistance.

6.1. Formation and Maintenance of Inflammatory Microenvironment. It has been demonstrated that inflammation in cancer is driven by IL-1β. "IL-1 signature" is found in patients with HER2− BC [79]. Primary BC cells secrete high levels of the chemokines RANTES/CCL5, CCL2, and granulocyte-colony stimulating factor (G-CSF) that recruit and activate monocytes and instruct them to secrete high levels of IL-1β and IL-8. This interaction also promotes the secretion of high levels of matrix metalloproteinase-1 (MMP-1), MMP-2, and MMP-10, ultimately creating a chronic inflammatory microenvironment that supports malignant progression and invasiveness [80]. One of the Th2 inflammatory pathways favoring tumor protection in BC relies on the secretion of IL-1β from primary BC induced by T cell cytokines and thymic stromal lymphopoietin (TSLP). Furthermore, IL-1β produced by myeloid cells is involved in the activation of inflammasomes by BC cell-derived factors. Breast cancer cell membrane-associated transforming growth factor-beta (TGF-β) is required for IL-1β production by DCs. IL-1-dependent transcriptional signaling has also been shown in the blood of patients with metastatic BC [81]. BC cell-derived IL-1α also induces expression of TSLP from tumor infiltrating myeloid cells, and TSLP, in turn, induces expression of B cell lymphoma-2 (Bcl-2) in tumor cells, promotes tumor cell survival, and skews the TME toward Th2 inflammation, sustaining lung metastatic survival [82]. Inflammasomes are one of the key regulators of IL-1 production. BC cells induce release of IL-1β from myeloid and T cells via activation of the NLRP3
inflammasome, and IL-1β activates the transcription factors aryl hydrocarbon receptor (AhR) and retinoid-related orphan nuclear receptor gamma t (RORγt) to induce IL-22 production in memory cluster determinant 4-positive (CD4+) T cells to promote tumor growth [83]. Activation of inflammasomes as well as increased level of IL-1β at the primary and metastatic sites promote the infiltration of myeloid cells such as MDSCs and TAMs into the TME [84].

Transactivation p73β (TAp73β) has been shown to directly activate the positive transcription of caspase-1 and upregulate the expression of pro-IL-1β mRNA and IL-1β protein, and thus may be important for the regulation of the inflammasomes and inflammation in tumor [85]. In addition, soluble CD44 (sCD44) antigen derived from the TNBC cell membrane triggers the production of macrophage-derived IL-1β, regulates the inflammatory TME, and promotes the growth of primary tumor [86]. However, the role of inflammation in HER2-induced tumorigenesis remains controversial. New studies have found that in HER2+ BC, overexpression of HER2 induces the expression and secretion of IL-1α, triggers the activation of other signal sequences including IL-6, and stimulates the NF-κB and STAT3 pathways to generate and maintain cancer stem cells (CSCs) and chronic inflammation to promote cancer initiation and progression [87]. In addition, the BC microenvironment in the context of obesity is associated with the increase of tumor infiltrating myeloid cells, which have
an activated NLRC4 inflammasome and IL-1β, which drive disease progression through activation of c-Jun N-terminal kinase (JNK)-mediated expression of VEGFA and angiogenesis in adipocytes [88]. The level of chronic inflammation usually also means a higher risk of recurrence of BC after primary treatment [87, 89].

6.2. Involvement in Tumor Immunosuppression/Escape. The systemic inflammatory cascade is orchestrated through a CCL2–macrophage–IL-1β–γδT cell–IL-17–immunosuppressive neutrophil axis in BC. CCL2 recruits C-C chemokine receptor 2-positive (CCR2+) monocytes from the bone marrow to elsewhere in the body and induces their differentiation into macrophages, promoting the expression of IL-1 derived from TAMs. γδT cells are subsequently induced to expand and produce IL-17, promoting the systemic expansion of immunosuppressive neutrophils and formation of metastasis [90]. Whereas IL-1β deficiency leads to low levels of CCL2, hinders recruitment of monocytes and, together with low levels of CSF-1, inhibits differentiation of monocytes into macrophages and results in a relatively high proportion of CD11b+ DCs, whose secretion of IL-12 supports antitumor immunity [91]. In addition, upregulation of IL-1R8 in mammary epithelial cell transformation and primary BC decreased IL-1-dependent activation of NF-κB and proinflammatory cytokine production, inhibited activation of NK cells, and promoted M2-like polarization of macrophages, resulting in impaired innate immune sensing and T cell rejection of the TME [92]. Proinflammatory cytokines expressed by primary breast tumors activate an IL-1β-dependent innate immune response in innate immune cells infiltrating the microenvironment of distant metastasis-initiating cancer cells (MICs), which may prevent the development of secondary disease and, conversely, primary tumor resection may prompt recurrence [93]. Another study also showed that the expression of IL-1β by MICs in BC was significantly associated with longer relapse-free survival and overall survival, while the lack expression of IL-1β
by MICs are associated with the worst prognosis, and may contribute to tumor immune escape [94]. Thus, IL-β secreted by BC cells at the primary and metastatic sites may have a positive effect on tumor immune escape and metastasis suppression, whereas IL-β secreted by immune cells infiltrating the TME exerts a detrimental effect. These new evidences suggest a new line of thinking to link the immuno-suppressive/escape microenvironment of BC with IL-1 and thus design tumor suppressive approaches.

6.3. Promotion of Metastasis. The infiltration of IL-1β inflammatory factors can directly promote the metastasis of BC. In TNBC, the increase of IL-1β directly affects the invasiveness of tumor cells [95]. IL-1β is both transmission supportive and colonization inhibitory. At the metastatic site, IL-1β maintains the systemic environment disseminated MICs in an active differentiated state of zinc-finger E-box binding protein 1 (ZEB1), preventing MICs from producing highly proliferative progeny with active E-cadherin [93]. In addition, the cytokine network composed of IL-1 together with other cytokines has a complex role in metastasis of BC cells. IL-6, oncostatin M (OSM), and IL-1β are correlative in expression. OSM induces phosphorylation of STAT3, and IL-1β promotes phosphorylation of p65 to synergistically induce IL-6 secretion of ER-MDA-MB-231 cells, promoting the onset of acute and chronic inflammation and metastasis [96]. Evaluation of serum samples from BC patients showed significant positive correlations between levels of IL-1β and (C-X-C motif) ligand 8 (CXCL8), and between levels of IL-1β and sCD200 in controls. Serum levels of sCD200, CXCL8, IL-1β, and CRP were significantly higher in early and advanced BC patients compared to controls [97]. Human IL-1β induces expression and secretion of stem cell factors (SCFs) in MCF-7 human epithelial BC cells in a manner dependent on the PI3K/mTOR pathway and hypoxia-inducible transcription factor-1alpha (HIF-1α) accumulation/activation [98]. IL-1β confers stem-cell-like ability of tumor cells to enhance their metastatic potential. However, another study showed that IL-1β increased migration of MDA-MB-231 cells, accumulation of HIF-1α, upregulation of CXCR1, and expression of CXCL8 and NF-κB under hypoxia. But inhibition of HIF-1α had no effect on IL-1β-migration of induced hypoxic cells and could not reduce expression of NF-κB and CXCL8. The NF-κB/CXCL8 pathway in a hypoxic microenvironment may play a compensatory role in the IL-1β-induced migration of MDA-MB-231 cells [99].

Several studies have shown that a complex interplay between MSCs and BC cells is closely related to the metastatic potential of BC cells. Compared with normal and other
subtypes of BC, the highest level of BRCA1-IRIS (hereafter IRIS) expression was observed in TNBC, the cellular necrotic/hypoxic/inflammatory centre of IRIS overexpressing (IRISOE) tumors or the vicinity formed an invasive niche, and IL-1β secreted by IRISOE-TNBC cells recruited and activated bone marrow MSCs to secrete CXCL1. CXCL1 enabled IRISOE-TNBC cells to secrete higher levels of CCL2 and VEGF, which recruit and activate TAMs and endothelial cells (ECs), and induce these cells to secrete S100A8/9 and IL-8, respectively. This interaction contributes to the generation of the metastatic precursor of IRISOE-TNBC [100]. Invasive BC cells (MDA-MB-231 cells) activate NF-κB signaling in MSCs by secreting IL-1β, inducing and increasing the production of the same chemokines (CXCL1, 3, 5, 6, 8, and CCL2, 5, etc.) as metastatic ER+ BC [101]. Cocultured TNBC cells and MSCs/CAF in the presence or stimulation of TNF-α or IL-1β showed increased expression of the prometastatic chemokines CXCL8, CCL2, and CCL5, enhanced angiogenesis, migration and invasion of cancer cells, and a significantly enhanced metastatic phenotype in TME and tumor cells themselves. Among them, CXCL8 plays a key mediating role [102]. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) were cocultured with breast or ovarian cancer cells, and the switched inflammatory UC-MSCs had no obvious effect on the proliferation or apoptosis of the two cancer models, but IL-1β produced in an autocrine manner promoted stem-cell-like properties of cancer cells, initiating the formation of a premetastatic niche [103].

There is a causal relationship between the inflammatory microenvironment and metastasis. Research found that loss of p53, a key regulator of prometastatic neutrophils, induced secretion of Wingless and int-1 (Wnt) ligands from cancer cells, which stimulated TAMs to produce IL-1β, which drives systemic inflammation. Pharmacologically and genetically blocking the secretion of Wnt reverses IL-1β expression by macrophages and subsequent neutrophilic inflammation, leading to reduced metastasis formation [104]. High expression of the transcription factor c-Myb was found to repress the expression of a set of inflammatory signature genes in BC, including Ccl2, Cxcl1, cxcl2, cxcl6, Cxcl16, Icam1, Il1a, Tnfrsf9, Lcn2, and Ikbbe, which were denoted as c-Myb-inflammatory signature [105]. It was subsequently found that c-Myb reduced autocrine signal transduction of the NF-κB pathway in BC and the ability of BC cells to migrate and cross the endothelial barrier through inhibition of the expression of IL-1α. Overexpression of IL-1α as well as the addition of recombinant protein of IL-1α activated NF-κB signaling and restored the expression of inflammatory signature genes that were suppressed by c-Myb [53]. Mouse models of BC reflect that periodontal inflammation (PI) and the resulting IL-1β promote the expression of CCL5, CXCL12, CCL2, and CXCL5, which in turn recruit MDSCs and macrophages, ultimately creating a premetastatic niche at the site of inflammation [106].

Tumor lymphangiogenesis is associated with metastasis, but the exact mechanism remains unclear. The novel study identified that sphingosine 1-phosphate receptor 1 (SIPR1) signaling in macrophages promoted lymphangiogenesis via NLRP3-dependent IL-1β secretion in mouse mammary tumors infiltrated with CD11b+CD206+ TAMs. And since IL-1β is involved in tumor pathological rather than physiological lymphangiogenesis, the side effects of targeting IL-1β to block tumor lymphangiogenesis may be limited [107]. Macrophase-derived caspase-1-dependent IL-1β plays an important role in BC cell lymphatic endothelial cell adhesion and migration across endothelial cell barriers [108]. Tumor-associated leukocytes isolated from lymph node+ BC patients secreted 2- to 5-fold more cytokines than lymph node-patients, with the most increased cytokines being thymus and activation-regulated chemokine (TARC/CCL17), IGF-1, IL-3, TNF-β, IL-5, G-CSF, IL-4, and IL-1α. These cytokines promote epithelial mesenchymal transition (EMT) and BC lymph node metastasis by upregulating TGF-β and vimentin, downregulating E-cadherin, and activating epidermal growth factor receptor (EGFR) (Tyr845) and NF-κB/p65 (ser276) signaling [109]. Circulating tumor cells (CTCs) are precursors to the formation of metastatic lesions and, therefore, are also prognostic markers of poor survival in patients with early-stage BC before the initiation of systemic adjuvant therapy and after adjuvant chemotherapy. Studies have found that IL-1α is a marker of tumor cells released into the circulation rather than into the lymphatic system [110]. Neutrophils can assist the formation of a precancerous metastatic niche in distant organs of BC due to activated neutrophils escorting CTCs, facilitating the adhesion of CTCs and ECs, and most CTC-associated leukocytes are N2-like neutrophils. Ki-67 expression was higher in disseminated tumor cells derived from CTC-neutrophil clusters compared with independent CTCs. In contrast, CTC-associated neutrophils frequently expressed TNF-α, OSM, IL-1β, and IL-6, which matched their receptors on the corresponding CTCs [111].

Studies have confirmed the importance of IL-1 signaling in the promotion of BC bone metastasis. Using a clinically relevant humanized mouse model of BC bone metastasis, altered expression of IL-1β, IL-1R1, S100A4, cathepsin K (CTSK), secreted phosphoprotein 1 (SPP1), and receptor activator of NF-κB (RANK) in BC cells as they progress from primary tumor to bone metastasis was demonstrated, and these molecules can be used to predict future bone recurrence in BC patients [112]. This model established that the presence and active function of IL-1β had an impact on the occurrence of bone metastases. In-depth studies have shown that bone marrow-derived IL-1β stimulates bone colonization of BC cells by inducing NF-κB/cyclic AMP response-element binding protein- (CREB-) Wnt signaling and colony formation of CSCs [113]. Furthermore, IL-1β produced endogenously by BC cells in primary sites promotes EMT, invasion, migration, and bone colonization. Upon arrival in the bone environment, contact between tumor cells and osteoblasts or myeloid cells increases the secretion of IL-1β by all three of these cell types. High concentrations of IL-1 β cause increased proliferation of the bone metastatic niche and bone resorption by osteoclasts, stimulating disseminated tumor cells to grow into overt metastases [114]. Additionally, IL-1 is also a differential regulator associated with pain of metastatic cancer in bone [115]. Bone marrow dissemination of BC cells is an early
event, but cells can become latently dormant for years before the development of bone metastases [114]. Treatment of bone metastases is not effective, and IL-1 signaling inhibitors may become new adjuvants to inhibit colonization of disseminated cells to metastases.

The lung is also a common metastatic site for BC. IL-1α and IL-1β secreted by metastatic BC cells induce the production of CXCL9 and CXCL10 by lung fibroblasts through the NF-κB signaling pathway. A small subset of BC cells specifically expressing CXCR3 exhibited tumor-initiating ability when cotransplanted with fibroblasts, driving JNK signaling, increasing expression of IL-1α/β, forming a supportive metastatic niche, and promoting lung metastatic tumor growth [116]. The inflammasome/IL-1 pathway is an important mechanism in the development of BC lung metastasis, as confirmed by the significant reduction of lung metastasis in inflammasome or caspase-1-deficient mice, and may be related to IL-1β-induced expression of CCL2 in macrophages and tumor cells [84]. In vitro invasion assay confirmed that irradiation targeting D2A1 tumor and its microenvironment increased the levels of plasma IL-1β, promoted the infiltration of tumor cells and the development of lung metastasis and increased the activity of MMP-2 and MMP9 [117]. Conversely, genetic studies utilizing the mouse mammary tumor virus poloma middle tumor (MMTV-PyMT) mouse model revealed that IL-1α-mediated IL-1R1 signaling inhibits the proliferation, growth, and lung metastasis of BC cells at early stages of tumorigenesis [118]. Therefore, the role of IL-1α-mediated IL-1 signaling in BC lung metastasis may be biphastic depending on the stage and context of tumor development.

6.4. Involvement in Tumor Resistance. BC is a HR-driven cancer, so many patients are treated with therapies that lower hormone levels or directly block HR, but most will eventually develop therapeutic resistance. A recent study proposed that IL-1 may provide a conserved basal gene expression pattern in HR+ BC cells that mimic HR- BC cells. Sequestome-1 (SQSTM1/p62) is a di expression pattern in HR+ BC cells that mimic HR- BC cells. Proposed that IL-1 may provide a conserved basal gene event, but cells can become latently dormant for years before the development of bone metastases [114]. Treatment of bone metastases is not effective, and IL-1 signaling inhibitors may become new adjuvants to inhibit colonization of disseminated cells to metastases.

In the cell model of BC cells (6D cells) with EMT induced by IL-1β through the activation of the IL-1β/IL-1R1/β-catenin pathway, upregulation of Twist1 resulted in methylation of the ESR1 gene promoter, which significantly reduced the level of ERα and increased the resistance to tamoxifen [120]. After IL-1β-high responsive clone (6D cells) from noninvasive MCF-7 BC cells were stimulated by IL-1β, the expression of CDKN1A/p21, TP63, small-fiber neuropathy (SFN), and especially BIRC3, was upregulated, which made BC cells resistant to doxorubicin [121]. The IL-1β/IL-1R1/β-catenin signaling pathway can also upregulate the expression of tumor protein 63 (TP63) isoform ΔNp63α, which in turn leads to increased expression of EGFR and phosphatase 1D (Wip1) and decreased DNA damage sensors and ataxia telangiectasia mutated (ATM). This is involved in the enhancement of the cisplatin resistance of BC cells [122]. Furthermore, IL-1β induces IL-6 production by transglutaminase 2- (TG2-) expressing MCF-7 cells through NF-κβ-, PI3K-, and JNK-dependent mechanisms, ultimately increasing the stem-cell-like phenotype of cancer cells associated with drug resistance [123].

7. Targeting IL-1 Signaling for Breast Cancer Treatment

7.1. Direct Blockade of IL-1 Signaling. There are currently four known IL-1 blocking biologics: anakinra, canakinumab, gevokizumab, and rilonacept. Anakinra, the recombinant form of the human IL-1Ra, acts by competitively preventing the binding of IL-1α and IL-1β to IL-1R1 [124]. Canakinumab is a human monoclonal antibody (mAb) specific for IL-1β [125]. Gevokizumab is a recombinant humanized allosteric monoclonal antibody that negatively regulates IL-1β signaling through an allosteric mechanism [78]. Rilonacept (ril on’a sept), an approved recombinant fusion protein comprising the extracellular portion of human IL-1R1 and IL-1RaCp fused to the Fc portion of human IgG1, binds to and inactivates IL-1, acting as an “IL-1 trap” [126]. Anakinra and canakinumab are currently approved for the treatment of rheumatoid arthritis, familial Mediterranean fever (FMF), cryopyrin-associated periodic syndrome, Still’s disease, and gouty arthritis, while gevokizumab does not currently have a specific indication [69, 127, 128]. Among them, canakinumab has been widely used in clinical experiments for lung cancer [129–131]. The protein formulation, i.e., the solution of IL-1Ra (kineret), may have ultra-long-term stability for 10 years and has clinical applications in metastatic BC (NCT01802970) [11, 132]. In addition, there are several other mAbs against two cytokines or their receptors, respectively, such as lutikizumab (ABT-981), a double variable domain Ig that binds to and inhibits both IL-1α and IL-1β [133]; anti-IL-1α Xilonix [134]; Bermekimab, a true human mAb targeting IL-1α cloned directly from human B cells (Epstein-Barr virus immortalized) isolated from humans with endogenous anti-IL-1α antibodies [135]; two IL-1β neutralizing antibodies, RD24 and P2D7KK [136]; and Nidanilimab, an entire humanized...
mAb against IL-1RAcP. Most of these antibodies are being used in clinical cancer therapy to block IL-1 signaling [11]. These blockers are shown in Figure 1.

Anakinra is an ideal treatment option with a short half-life for patients who have undergone chemotherapy, and it is increasingly used as an adjuvant therapy to reduce inflammation in metastatic cancer [79, 137]. In humanized mouse models of BC bone metastasis, anakinra treatment reduced the number of mice that developed metastases in human bone implants from 57.14% to 0% [112]. Anti-IL-1β treatment reduced hindlimb bone metastasis in the spontaneous MDA-MB-231 BH mouse model [113]. Knockout of IL-1R1 (IL-1R1−/−), anakinra or canakinumab reduced bone metastasis and the number of tumor cells shed into the circulation [114]. Blocking IL-1R with IL-1Ra inhibited the invasiveness of Hs578t and MDA-MB231 TNBC cells and the development of bone metastasis [95], and it inhibited tumor growth while reducing the accumulation of myeloid cells [84]. Treatment with anti-IL-1β antibody attenuates production of IL-6, the stem-like phenotype, and tumor growth and metastasis in TG2+ BC cells [123]. The use of anakinra in vivo reduced the production of IL-22 and tumor growth in BC [83]. Anakinra or TGF-β neutralizing antibody treatment significantly decreased the production of IL-13, IL-4, IL-17, and TSLP; increased the production of NF or interferon-gamma (IFNγ); and suppressed growth of BC [81]. Secretion of IL-1β by IRISOE-TNBC cells within the invasive niche initiates a bidirectional effect with MSCs. Anakinra could break these bidirectional interactions; inhibit generation of MSCs, tumor recruitment, and secretion of CXCL1 in vivo; and enhance the efficacy of chemotherapy on IRISOE-TNBC, especially on metastasis [100].

Neither prophylactic nor therapeutic administration of anakinra significantly inhibited the growth of MDA-MB-231-IV tumors in bone and reduced the number of mice that developed bone metastases and subcutaneous tumor volume [138]. Anti-IL-1R1 antibody and anakinra treatment inhibits the growth of E0771 tumor in DIO mice [88]. These evidences revealed that anakinra can modulate the BC microenvironment by blocking IL-1 signaling, reducing tumor growth and metastasis. Unfortunately, there have been few studies on rilencoplan and gevokizumab and other biologics used to block IL-1 for the treatment of BC except for the human antibody scFv 12H7, one specially prepared specific binder of IL-1RAcP with high affinity, which had growth inhibitory activity against TNBC cells in vitro and in vivo [139].

Anakinra provides an optimal treatment. The short half-life of subcutaneously injected anakinra is a distinct advantage, allowing oncologists to stop anakinra treatment at the first sign of infection. This is something that cannot be achieved with persistent antibodies, such as canakinumab [79]. But the results of experiments using anakinra alone may limit understanding of the pleiotropic role of IL-1 in BC, as it is not clear how much of its efficacy is due to blocking IL-1α and how much is due to blocking IL-1β [140]. Because chemotherapy often leads to myelosuppression, and IL-1 blockade therapy can also suppress peripheral blood neutrophils, the risk of infection may be increased when using IL-1 blockade therapy alone or when using anakinra in combination with standard chemotherapy regimens. Therefore, the precise timing and dosage of IL-1 blockade should be determined before application to cancer patients. In this context, modulation of cancer-cell-induced production of IL-1 might be a better option [86].

7.2. Blockade of Up- and Downstream Regulatory Signals of IL-1. Blocking IL-1 in tumors has now expanded immensely. Primary mammary tumor growth and lung metastases were significantly reduced in NLRP3 knockout mice and caspase-1 knockout mice designed to reduce mature IL-1 production [84]. Tumor growth was significantly reduced in caspase-1/Il11−/− and Nlrca4−/− diet-induced obese mice [88]. TGF-β neutralizing antibody treatment was able to decrease production of IL-1β in humanized mouse tumors [81]. Antibody-mediated neutralization of sCD44 abrogated production of IL-1β in macrophages, modulated the tumor inflammatory microenvironment, and inhibited primary tumor growth [86]. IL-1R8 deficiency in the transgenic mouse model of BC (MMTV-neu/IL-1R8−/−) delayed tumorigensis and reduced tumor burden and metastasis [92]. miRNAs are noncoding microRNAs that negatively regulate gene expression, and play important roles in self-renewal, growth, and metastasis of BC cells [141, 142]. miR-146a-5p can downregulate expression of IRAK1 by directly binding to its 3’-untranslated region and inhibit proliferation and invasion of BC cells [143]. NF-κB inhibitor Bay11-7085 reduced basal levels of IL-1β and invasiveness of TNBC cells [95]. Furthermore, since IL-1-induced p62 mediated survival and HR treatment resistance of BC cells, the p62 targeting drug verteporfin (visudyne®) was cytotoxic to HR-BC cell lines [52]. These results illustrate that targeting NLRP3, NLRCA4, caspase-1, TGF-β, sCD44, IL-1R8, IRAK1, and NF-κB, which affect production and activation of IL-1, and IL-1-mediated downstream signaling p62, are also effective ways to modulate IL-1 signaling in the BC microenvironment.

7.3. Combination Therapy. It has been mentioned before that anti-IL-1 or anakinra may decrease the resistance of BC and improve the efficacy of chemotherapy. Furthermore, it was shown that the median duration of treatment with anakinra in combination with one of the standard chemotherapeutic agents (albumin-bound paclitaxel, eribulin, or capecitabine) for BC was 4 months in 11 women with metastatic HER2- BC. Gene expression of IL-1β, IL-1R1, IL-1R2, and IL-1RAcP, the five members of the TLR family and the IL-1 signaling kinases MyD88 and spleen tyrosine kinase (SYK) were decreased during two weeks of daily anakinra and during the pilot trial. Conversely, the expression of some NK cell and cytotoxic T cell genes that favor immune-mediated tumor destruction was increased [79]. It is suggested that chemotherapy combined with anakinra treatment may also have the effect of restoring antitumor immunity. In addition, anakinra may also enhance the effects of other treatment modalities, such as immunotherapy. Treatment of wild type mice with 4T1 tumors first with anti-IL-1β antibody and then with antiprogrammed cell death protein 1 (PD-1) antibody resulted in a therapeutic outcome that differed from the partial growth inhibition
Table 1: Treatments or interventions targeting or affecting IL-1 signaling in breast cancer.

| Treatment/intervention                  | Targets          | In vivo/ in vitro | Models                                                                 | Findings                                                                                     | References |
|-----------------------------------------|------------------|-------------------|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------|
| Anakinra; anti-TGFβ                     | IL-1R1           | In vivo           | Hs578T; NOD/SCID/β2m-/-; patients with HER2 metastatic BC (NCT01802970) | Prevented tumor progression and production of IL-13 in humanized mouse model; downregulated specific components of the systemic inflammatory signature observed in patients with metastatic BC and rescued cytotoxic programs thought to be critical for antitumor activity | [81]       |
| Anti-IL-1R; anakinra                    | IL-1 signaling   | In vivo           | 4T1; E0771; BALB/c; C57BL/6                                           | Reduced tumor progression and production of IL-22+ cells                                    | [83]       |
| IL1Ra; caspase-1 inhibitor; Ac-YVAD-cmk; anti-IL-1β; anticaspase-1; caspase-1-/-; NLRP3-/- | IL-1 signaling   | In vivo and in vitro | EO771; PyT8; MDA-MB-231; C57BL/6; NSG; MMTV-PyMT                    | Reduced tumor growth and lung metastasis accompanied by decreased myeloid cell accumulation  | [84]       |
| Anti-CD44                                | CD44             | In vitro          |                                                                         | Abrogated IL1β production in macrophages and inhibited growth of primary tumors              | [86]       |
| IRAK1 inhibitor synergized with either cisplatin or paclitaxel | IL-1α signaling | In vivo           | FVB/N                                                                 | Reduction of CSCs and improvement of the chemotherapy efficacy                             | [87]       |
| Anti-IL-1R1; anakinra; caspase 11-/-; NLRP3-/-; NLRCA-/-     | NLRCA/IL-1β      | In vivo           | Py8119; E0771; C57BL/6N                                              | Reduced tumor growth except NLRP3-/- mice                                                  | [88]       |
| Anti-IL-1β, anti-PD-1                    | IL-1β, PD-1      | In vivo           | 4T1; BALB/c                                                            | Anti-IL-1β Abs and anti-PD-1 Abs have a synergistic antitumor activity                     | [91]       |
| IL-1R8-/-                                | IL-1R8           | In vivo and in vitro | HB4a; HB4a-C5.2; NKL; THP-1; MMTV-neu                                | Reduced tumor growth and metastasis                                                        | [92]       |
| IL-1Ra; Bay; Zerumbone                   | NF-kB signaling pathway | In vitro         | Hs578T; MDA-MB-231                                                   | Inhibition of IL-1β expression and cell invasiveness                                       | [95]       |
| Anakinra                                | IL-1R1           | In vivo           | MScs; IRISOE cell lines; SCID                                         | Decreased recruitment of mouse MSCs into IRISOE-TNBC tumors and their activation to produce and secrete CXCL1 on cancer cells | [100]      |
| IL-1Ra                                  | IL-1R1           | In vitro          | MDA-MB-231 and UC-MSCs coculturing system                             | Blocked prosteness effects of UC-MSCs on cancer cells                                      | [103]      |
| Anakinra                                | IL-1R1           | In vivo and in vitro | T47D; MCF-7; BB36C32; BB2RC08; BB6RC37                               | Reduced bone metastasis                                                                    | [112]      |
| Sulfasalazine; KG-501                    | NF-kB; CREB      | In vitro          | MCF-7; MDA-MB-231_BH                                                | Inhibited Wnt-dependent CSC colony formation in the bone environment                        | [113]      |
| Anti-IL-1β                               | IL-1β            | In vivo           | NSG                                                                   | Reduced tumor formation; increased trabecular bone volume                                   |           |
| IL-1Ra; canakinumab                      | IL-1β signaling  | In vivo           | MDA-MB-231; E0771; NOD/SCID; BALB/c nude                            | Reduced spontaneous metastasis to human bone                                               | [114]      |
| Caspase-1 inhibitor                      | Caspase-1        | In vitro          | MDA-MB-231                                                            | Abrogated level of transmigration of MDA-MB-231 cells through both blood and lymphatic endothelial cell barriers |           |
| Verteporfin; siRNA-silenced p62          | SQSTM1/p62       | In vitro          | MCF-7; MDA-MB-231                                                   | Cytotoxic for HR- cell lines                                                               | [52]       |
| IRAK1/4 inhibitor; BAY11-7082; Sp600125; and LY294002 | NF-kB, JNK; PI3K | In vitro          | MCF-7 (ATCCHTB-22); MCF-7_TG2                                       | Inhibited expression of IL-6 from IL-1β-stimulated TG2-overexpressing MCF-7_ TG2 BC cells | [123]      |
resulting from each antibody alone in that, instead, the tumor progression was completely abrogated [91]. Chimeric antigen receptor- (CAR-) T cells are genetically modified T cells with potential to target the TME and treat solid tumors. Toxicities arising in tumor CAR-T therapy, IL-1-mediated inflammation, and IL-1-induced IL-33-mediated anaphylaxis could be suppressed by the anti-inflammatory cytokine IL-37, thereby contributing to the amelioration of adverse effects of CAR-T therapy [144]. Anakinra can reduce the inflammation and immunosuppression caused by IL-1, contributing to the enhanced antitumor activity. More information on these treatments or interventions is shown in Table 1.

The combination with mAbs is a great focus of future development for IL-1-related therapies, both with immune checkpoint inhibitors, and with other molecularly targeted antibody classes of drugs. As tumor-hyperactivated IL-1 signaling is also responsible for the failure of targeted therapies, targeted therapies using monoclonal antibodies in combination with IL-1 blockade might have improved efficacy [145]. There are a number of recent studies that support this inference. For example, inhibition of IL-1R1 reduced the resistance of metastatic colorectal cancer (mCRC) to cetuximab (a monoclonal antibody-targeting EGFR) [146]. IL-1α induced a T cell-dependent antitumor immune response increasing the antitumor efficacy of cetuximab against head and neck squamous cell carcinoma (HNSCC) [147]. In a phase II study, the good activity and manageable safety profile of fluorouracil (5-FU) in combination with bevacizumab and anakinra were demonstrated in mCRC patients who did not respond to chemotherapy and antiangiogenic therapy [137]. But such studies are lacking in BC.

As mentioned earlier, fatal systemic inflammation is a drawback of this therapy. IL-1R1 blockade in combination with chemotherapy may also increase toxicity [81]. Therefore, whether anakinra is a safe adjuvant to chemotherapy and other treatments remains to be demonstrated.

8. Conclusions and Perspectives

As a key regulatory inflammatory cytokine, IL-1 is produced in response to not only the stimulus of cell damage, necrosis or environmental stress but also the demand of certain tumors, including BC, and in turn it activates downstream and surrounding inflammatory signals that act to recruit, promote inflammation, induce immunosuppression, promote metastasis, and participate in drug resistance, thus providing a favorable environment for tumor survival.

IL-1-mediated inflammatory signaling participates in immunosuppression and immune escape through the production and maintenance of an inflammatory microenvironment, which is conducive to the progress of BC. Therefore, blocking of abnormal IL-1 signaling caused by a tumor can be used as an immunotherapy or adjuvant immunotherapy to reduce inflammation/immunosuppression and enhance antitumor immunity [148]. In the context of BC, the dysregulated expression of genes, transcription factors, inflammatory cytokines, chemokines, and signaling pathway proteins that depend on or involve in the regulation of the production, secretion, and function of IL-1 signaling molecules, as well as the IL-1-mediated crosstalk between tumor cells and tumor infiltrating immune cells plays an important role in determining the metastatic potential and therapeutic resistance. To date, the role of IL-1 signaling in tumors has been controversial, in part due to differences in cancer contexts, pleiotropic effects of IL-1, and distinct functions of the two IL-1 cytokines. Most of what is currently known about the role of IL-1 signaling in tumors comes from studying the function of individual recombinant or extracellular forms of IL-1 cytokines, actually leading to an inability to determine their relevance to the function of cells as well as established malignant cells, either from cancer patients or from transplantable mouse models [118].

The levels of IL-1 in combination with other cytokines or IL-1α/β alone in TME or serum in BC patients are correlated...
with treatment outcome and are likely to be predictive of poorer outcome. The clinical implications of biomarkers that can classify cases in need of action versus those that are best addressed individually are gaining traction [149, 150]. Currently, only a minority of molecules form part of routine molecular diagnosis of BC, and microenvironment-derived biomarkers are potential additions to existing panels of predictive and prognostic markers [35]. Interestingly, a study conducted in 2017–2018 explored the relationship between cognitive function, severity of depressive symptoms, and IL-1 expression in patients with BC treated with systemic anticancer therapy. The protein expression levels of IL-1α and IL-1β in patients after chemotherapy were significantly lower, and the severity of depressive symptoms was also lower than that before chemotherapy [151]. We need a more detailed understanding of how different types of cells interact in the microenvironment and how IL-1 signaling promotes or suppresses tumors to better use immune cells and IL-1 as targets and biomarkers for BC therapy.

Among the related therapeutic strategies, the results of several in vivo and in vitro experiments demonstrated the potential of IL-1 as a therapeutic target for metastatic BC. Anakinra is the most widely used FDA approved biological agent for cancer-related inflammation, which targets the BC microenvironment by directly blocking IL-1 signaling, reducing tumor growth and metastasis, and enhancing chemotherapy efficacy. But this therapeutic approach may interfere with the IL-1-mediated innate immunity in vivo, which is the biggest limitation. Compared with several other blockers, anakinra mimics the natural mode of IL-1 blockade with more direct apparent effects and representativeness, which may have contributed to the lower cost-effectiveness and use of other blockers in clinical studies. On the other hand, none of the primary aims of various related studies were to investigate the antitumor effects of IL-1 blockade on a targeted basis. We therefore believe that focusing on the antitumor effects of the blockade of IL-1 signaling in future studies is warranted. There are also other candidate targeting strategies in terms of IL-1 signaling blockade, such as IL-1RαC, IL-1R2/8, inflammatory/caspase-1, IRAK, and NF-κB pathways. At present, BC has a high recurrence rate and rapid disease progression after monotherapy; thus, combination therapy has become a hallmark of BC treatment. Drug combinations using different mechanisms are able to reduce the likelihood of cancer cells developing drug resistance while reducing the therapeutic dose and toxicity of monotherapies [152].

Targeting the tumor microenvironment often requires innovative drug delivery systems, such as nanoformulations, to achieve drug accumulation at the tumor site. How to link nanomedicine to tumor delivery of anti-IL-1 drugs is also a question to be addressed in the future [153]. Altogether, further understanding of the mechanisms by which IL-1 signaling regulates inflammation, immunity, metastasis, and drug resistance in the BC microenvironment, and finding novel targets that are closely related to tumor development and whose blockade does not later have a devastating impact on the role of IL-1 signaling in innate immunity will provide new perspectives for therapeutic strategies in BC, especially in metastatic BC.

Conflicts of Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments
This work was supported by the Projects of International Cooperation and Exchanges of the National Natural Science Foundation of China (grant number 82020108033), the Science and Technology Program of Guangzhou (grant number 202103000091) and the Natural Science Foundation of Guangdong (grant number 2019A1515011286).

References
[1] C. A. Dinarello, “IL-1: discoveries, controversies and future directions,” European Journal of Immunology, vol. 40, pp. 599–606, 2010.
[2] J. K. Fields, S. Günther, and E. J. Sundberg, “Structural basis of IL-1 family cytokine signaling,” Frontiers in Immunology, vol. 10, p. 1412, 2019.
[3] A. Mantovani, C. A. Dinarello, M. Molgora, and C. Garlanda, “Interleukin-1 and related cytokines in the regulation of inflammation and immunity,” Immunity, vol. 50, pp. 778–795, 2019.
[4] C. H. Hannum, C. J. Wilcox, W. P. Arend et al., “Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor,” Nature, vol. 343, pp. 336–340, 1990.
[5] J. E. Sims and D. E. Smith, “The IL-1 family: regulators of immunity,” Nature Reviews Immunology, vol. 10, pp. 89–102, 2010.
[6] I. Striz, “Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations,” Clinical Science, vol. 131, pp. 2241–2256, 2017.
[7] F. L. van de Veerdonk and M. G. Netea, “New insights in the immunobiology of IL-1 family members,” Frontiers in Immunology, vol. 4, p. 167, 2013.
[8] D. Boraschi, P. Italiani, S. Weil, and M. U. Martin, “The family of the interleukin-1 receptors,” Immunological Reviews, vol. 281, pp. 197–232, 2018.
[9] R. N. Apte, S. Dotan, M. Elkabets et al., “The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions,” Cancer Metastasis Reviews, vol. 25, pp. 387–408, 2006.
[10] A. Mantovani, I. Barajon, and C. Garlanda, “IL-1 and IL-1 regulatory pathways in cancer progression and therapy,” Immunological Reviews, vol. 281, pp. 57–61, 2018.
[11] A. Litmanovich, K. Khazim, and L. Cohen, “The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice,” Oncology and therapy, vol. 6, pp. 109–127, 2018.
[12] J. J. McDonald, D. C. McMillan, and B. J. A. Laird, “Targeting IL-1α in cancer cachexia: a narrative review,” Current Opinion in Supportive and Palliative Care, vol. 12, pp. 453–459, 2018.
[13] J. Mora and A. Weigert, “IL-1 family cytokines in cancer immunity - a matter of life and death,” Biological Chemistry, vol. 397, pp. 1125–1134, 2016.
[14] O. S. Dmitrieva, I. P. Shilovskiy, M. R. Khaitov, and S. I. Gribennikov, “Interleukins 1 and 6 as main mediators of inflammation and cancer,” The Biochemist, vol. 81, pp. 80–90, 2016.

[15] A. Valeta-Magara, A. Gadi, V. Volta et al., "Inflammatory breast cancer promotes development of M2 tumor-associated macrophages and cancer mesenchymal cells through a complex chemokine network," Cancer Research, vol. 79, pp. 3360–3371, 2019.

[16] K. Taniguchi and M. Karin, “NF-κB, inflammation, immunity and cancer: coming of age,” Nature Reviews Immunology, vol. 18, pp. 309–324, 2018.

[17] C. Belli, D. Trapani, G. Viale et al., “NF-κB, inflammation and cancer: a mechanism involving the proinflammatory cytokines IL-1β and TNF-α,” Journal of Immunology Research, vol. 2019, Article ID 6384278, 11 pages, 2019.

[18] W. Zhang, N. Borcherding, and R. Kolb, “IL-1 signaling in tumor microenvironment,” Advances in Experimental Medicine and Biology, vol. 1240, pp. 1–23, 2020.

[19] I. Martinez-Reza, L. Diaz, D. Barrera et al., “Calcitriol inhibits the proliferation of triple-negative breast cancer cells through a mechanism involving the proinflammatory cytokines IL-1β and TNF-α,” Journal of Immunology Research, vol. 2019, Article ID 6384278, 11 pages, 2019.

[20] K. J. Baker, A. Houston, and E. Brint, “IL-1 family members in cancer: two sides to every story,” Frontiers in Immunology, vol. 10, p. 1197, 2019.

[21] A. Ahmad, “Breast cancer statistics: recent trends,” Advances in Experimental Medicine and Biology, vol. 1152, pp. 1–7, 2019.

[22] J. Huang, P. S. Chan, V. Lok et al., “Global incidence and mortality of breast cancer: a trend analysis,” Aging (Albany NY), vol. 13, pp. 5748–5803, 2021.

[23] O. Peart, “Metastatic Breast Cancer,” Radiologic technology, vol. 88, no. 5, pp. 519m–539m, 2017.

[24] B. Wörmann, “Breast cancer: basics, screening, diagnostics and treatment,” Medizinische Monatsschrift für Pharmazeuten, vol. 40, pp. 55–64, 2017.

[25] C. D. Savci-Heijink, H. Halfwerk, G. K. Hooijer, H. M. Horlings, J. Wesseling, and M. J. van de Vijver, “Retrospective analysis of metastatic behaviour of breast cancer subtypes,” Breast Cancer Research and Treatment, vol. 150, pp. 547–557, 2015.

[26] A. G. Waks and E. P. Winer, “Breast cancer treatment: a review,” Journal of the American Medical Association, vol. 321, pp. 288–300, 2019.

[27] K. J. Ruddy and P. A. Ganz, “Treatment of nonmetastatic breast cancer,” Journal of the American Medical Association, vol. 321, pp. 1716–1717, 2019.

[28] N. Harbeck and M. Gnant, “Breast cancer,” Lancet, vol. 389, pp. 1134–1150, 2017.

[29] S. Nagini, “Breast cancer: current molecular therapeutic targets and new players,” Anti-Cancer Agents in Medicinal Chemistry, vol. 17, pp. 152–163, 2017.

[30] O. Peart, “Breast intervention and breast cancer treatment options,” Radiologic Technology, vol. 86, pp. 535M–558M, 2015, quiz 559–62.

[31] F. A. Fisusi and E. O. Akala, “Drug combinations in breast cancer therapy,” Pharmaceutical nanotechnology, vol. 7, pp. 3–23, 2019.

[32] M. Fahad Ullah, “Breast cancer: current perspectives on the disease status,” Advances in Experimental Medicine and Biology, vol. 1152, pp. 51–64, 2019.

[33] M. Nedeljkovic and A. Damjanovic, “Mechanisms of chemotherapy resistance in triple-negative breast cancer—how we can rise to the challenge,” Cell, vol. 8, p. 957, 2019.

[34] J. J. Wang, K. F. Lei, and F. Han, “Tumor microenvironment: recent advances in various cancer treatments,” European Review for Medical and Pharmacological Sciences, vol. 22, pp. 3855–3864, 2018.

[35] S. Mittal, N. J. Brown, and I. Holen, “The breast tumor microenvironment: role in cancer development, progression and response to therapy,” Expert Review of Molecular Diagnostics, vol. 18, pp. 227–243, 2018.

[36] T. G. Odle, “Precision medicine in breast cancer,” Radiologic technology, vol. 88, no. 4, pp. 401m–421m, 2017.

[37] H. Rachdi, A. Mokrani, R. Batti, M. Ayadi, N. Chraiet, and A. Mezlini, “Targeted therapy for metastatic breast cancer,” La Tunisie Médicale, vol. 96, pp. 465–471, 2018.

[38] G. Gu, D. Dustin, and S. A. Fuqua, “Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment,” Current Opinion in Pharmacology, vol. 31, pp. 97–103, 2016.

[39] L. The, “Breast cancer targeted therapy: successes and challenges,” Lancet, vol. 389, p. 2350, 2017.

[40] K. G. Deepak, R. Vempati, G. P. Nagaraju et al., “Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer,” Pharmacological research, vol. 153, article 104683, 2020.

[41] M. Truffi, S. Mazzucchelli, A. Bonizzi et al., “Nano-strategies to target breast cancer-associated fibroblasts: rearranging the tumor microenvironment to achieve antitumor efficacy,” International Journal of Molecular Sciences, vol. 20, p. 1263, 2019.

[42] Q. Q. Liu, F. Peng, and J. P. Chen, “The role of exosomal microRNAs in the tumor microenvironment of breast cancer,” International Journal of Molecular Sciences, vol. 20, p. 3884, 2019.

[43] J. Plava, M. Cihova, M. Burikova, M. Matuskova, L. Kucerova, and S. Miklikova, “Recent advances in various cancer treatments, Mediators of Inflammation, vol. 18, pp. 121–134, 2019.

[44] J. Wesseling, and M. J. van der Vijver, “Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer,” Molecular Cancer, vol. 18, p. 67, 2019.

[45] D. Bauer, N. Redmon, E. Mazzio, and K. F. Soliman, “Apgin inhibits TNFα/IL-1α-induced CCL2 release through IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells,” PLoS One, vol. 12, article e0175558, 2017.

[46] D. T. Chu, T. N. T. Phuong, N. L. B. Tien et al., “The effects of adipocytes on the regulation of breast cancer in the tumor microenvironment: an update,” Cells, vol. 8, p. 857, 2019.

[47] T. Wu and Y. Dai, “Tumor microenvironment and therapeutic response,” Cancer Letters, vol. 387, pp. 61–68, 2017.

[48] E. Hirata and E. Sahai, “Tumor microenvironment and differential responses to therapy,” Cold Spring Harbor Perspectives in Medicine, vol. 7, p. a026781, 2017.

[49] N. J. Brady, P. Chuntova, and K. L. Schwertfeger, “Macrophages: regulators of the inflammatory microenvironment during mammary gland development and breast cancer,” Mediators of Inflammation, vol. 2016, Article ID 4549676, 13 pages, 2016.

[50] N. Singh, D. Baby, J. P. Rajguru, P. B. Patil, S. S. Thakkanna, and V. B. Pujari, “Inflammation and cancer,” Annals of African Medicine, vol. 18, pp. 121–126, 2019.
[50] M. D. Allen and L. J. Jones, “The role of inflammation in progression of breast cancer: friend or foe? (review),” *International Journal of Oncology*, vol. 47, pp. 797–805, 2015.

[51] S. K. Deshmukh, S. K. Srivastava, T. Poosarla et al., “Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy,” *Annals of translational medicine*, vol. 7, p. 593, 2019.

[52] A. F. Nawas, M. Kanchwala, S. E. Thomas-Jardin et al., “IL-1β-conferred gene expression pattern in Erα (+) BCA and AR (+) PCa cells is intrinsic to Erα (-) BCA and AR (-) PCa cells and promotes cell survival,” *BMC Cancer*, vol. 20, p. 46, 2020.

[53] M. Dúcka, M. Kucerikova, F. Trcka et al., “c-Myb interferes with inflammatory IL1α-NF-κB pathway in breast cancer cells,” *Neoplasia*, vol. 23, pp. 326–336, 2021.

[54] H. Li, N. Duan, Q. Zhang, and Y. Shao, “IL1A & IL1B genetic polymorphisms are risk factors for thyroid cancer in a Chinese Han population,” *International Immunopharmacology*, vol. 76, article 105869, 2019.

[55] H. Ji, L. Lu, J. Huang et al., “IL1A polymorphisms is a risk factor for colorectal cancer in Chinese Han population: a case control study,” *BMC Cancer*, vol. 19, p. 181, 2019.

[56] Y. Wang, X. Chu, and H. Wang, “Note of clarification regarding data on the association between the interleukin-1β-511C>T polymorphism and breast cancer risk,” *Breast Cancer Research and Treatment*, vol. 155, pp. 419–421, 2016.

[57] Y. Wang, Y. Wang, and L. Li, “Note of clarification regarding data about the association between the interleukin-1β-31T>C polymorphism and breast cancer risk,” *Breast Cancer Research and Treatment*, vol. 155, pp. 415–417, 2016.

[58] B. Wang and F. Yuan, “The association between interleukin-1β gene rs1143634 polymorphism and the risk of breast cancer,” *Cytokine*, vol. 113, pp. 475–476, 2019.

[59] S. Pooja, S. Rajender, and R. Konwar, “Response to commentary article: The association between interleukin-1β gene rs1143634 polymorphism and the risk of breast cancer by Bei Wang, Fenlai Yuan ,” *Cytokine*, vol. 113, p. 477, 2019.

[60] N. Eras, F. T. Daloglu, T. Colak, M. Guler, and E. Akbas, “The correlation between IL-1β-C31T gene polymorphism and susceptibility to breast cancer,” *Journal of breast cancer*, vol. 22, pp. 210–218, 2019.

[61] J. Wang, Y. Shi, G. Wang, S. Dong, D. Yang, and X. Zuo, “The association between interleukin-1β polymorphisms and their protein expression in Chinese Han patients with breast cancer,” *Molecular Genetics & Genomic Medicine*, vol. 7, article e804, 2019.

[62] L. N. Al-Eitan, B. H. Al-Ahmad, and F. A. Almomanii, “The association of IL-1 and HRAS gene polymorphisms with breast cancer susceptibility in a Jordanian population of arab descent: a genotype-phenotype study,” *Cancers*, vol. 12, 2020.

[63] A. Malik and T. D. Kanneganti, “Function and regulation of IL-1α in inflammatory diseases and cancer,” *Immunological Reviews*, vol. 281, pp. 124–137, 2018.

[64] M. J. Bou-Dargham, Z. I. Khamis, A. B. Cognetta, and Q. A. Sang, “The role of interleukin-1 in inflammatory and malignant human diseases and the rationale for targeting interleukin-1 alpha,” *Medicinal Research Reviews*, vol. 37, pp. 180–216, 2017.

[65] L. A. Borthwick, “The IL-1 cytokine family and its role in inflammation and fibrosis in the lung,” *Seminars in Immunopathology*, vol. 38, pp. 517–534, 2016.

[66] K. Khazim, E. E. Azubay, B. Kristal, and I. Cohen, “Interleukin-1 gene polymorphism and susceptibility to disease,” *Immunological Reviews*, vol. 281, pp. 40–56, 2018.

[67] V. Ziaeef, L. Yousefsefat, M. Faghankhani et al., “Homzygous ILIRN mutation in siblings with deficiency of interleukin-1 receptor antagonist (DIRA),” *Journal of Clinical Immunology*, vol. 40, pp. 637–642, 2020.

[68] N. Toplak, S. Blazina, and T. Avičin, “The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives,” *Drug Design, Development and Therapy*, vol. 12, pp. 1633–1643, 2018.

[69] B. Afsar, A. Covic, A. Ortiz, R. E. Afsar, and M. Kanbay, “The future of IL-1 targeting in kidney disease,” *Drugs*, vol. 78, pp. 1073–1083, 2018.

[70] M. Kanto and B. Guo, “Inflammomasomes and cancer: the dynamic role of the inflammmasome in tumor development,” *Frontiers in Immunology*, vol. 8, p. 1132, 2017.

[71] K. D. Mayer-Barber and B. Yan, “Clash of the cytokine titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses,” *Cellular & Molecular Immunology*, vol. 14, pp. 22–35, 2017.

[72] A. Malik and T. D. Kanneganti, “Inflammaosome activation and assembly at a glance,” *Journal of Cell Science*, vol. 130, pp. 3955–3963, 2017.

[73] C. A. Dinarello, “Overview of the IL-1 family in innate inflammation and acquired immunity,” *Immunological Reviews*, vol. 281, pp. 8–27, 2018.

[74] H. J. Anders, “Of inflammaosomes and alarms: IL-1β and IL-1α in kidney disease,” *Journal of the American Society of Nephrology*, vol. 27, pp. 2564–2575, 2016.

[75] J. W. Singer, A. Fleischman, S. Al-Fayoumi, J. O. Mascarenhas, Q. Yu, and A. Agarwal, “Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy,” *Onco-target*, vol. 9, pp. 33416–33439, 2018.

[76] S. A. Scarmeas, P. F. Hughes, K. W. Yang et al., “A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase,” *The Journal of Biological Chemistry*, vol. 295, pp. 1565–1574, 2020.

[77] T. Schluter, C. Schelmbauer, K. Karram, and I. A. Mufazalov, “Regulation of IL-1 signaling by the decoy receptor IL-1R2,” *Journal of Molecular Medicine*, vol. 96, pp. 983–992, 2018.

[78] H. Issafras, J. A. Corbin, I. D. Goldfine, and M. K. Roell, “Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 348, pp. 202–215, 2014.

[79] C. A. Dinarello, “An interleukin-1 signature in breast cancer treated with interleukin-1 receptor blockade: implications for treating cytokine release syndrome of checkpoint inhibitors,” *Cancer Research*, vol. 78, pp. 5200–5202, 2018.

[80] N. A. Espinoza-Sánchez, G. K. Chimal-Ramírez, A. Mantilla, and E. M. Fuentes-Panana, “IL-1β, IL-8, and matrix metalloproteinases-1, -2, and -10 are enriched upon monocyte-breast cancer cell cocultivation in a Matrigel-based three-dimensional system,” *Frontiers in Immunology*, vol. 8, p. 205, 2017.

[81] T. C. Wu, K. Xu, J. Martíneek et al., “IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer,” *Cancer Research*, vol. 78, pp. 5243–5258, 2018.
[82] E. L. Kuan and S. F. Ziegler, "A tumor-myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer," Nature Immunology, vol. 19, pp. 366–374, 2018.

[83] C. Voigt, P. May, A. Gottschlich et al., "Cancer cells induce interleukin-22 production from memory CD4(+) T cells via interleukin-1 to promote tumor growth," Proceedings of the National Academy of Sciences of the United States of America, vol. 114, pp. 12994–12999, 2017.

[84] B. Guo, S. Fu, J. Zhang, B. Liu, and Z. Li, "Targeting inflammasome/IL-1 pathways for cancer immunotherapy," Scientific Reports, vol. 6, article 36107, 2016.

[85] P. Vikhreva, V. Petrova, T. Gokbulut et al., "TAp73 upregulates IL-1β in cancer cells: potential biomarker in lung and breast cancer?", Biochemical and Biophysical Research Communications, vol. 482, pp. 498–505, 2017.

[86] J. H. Jang, D. H. Kim, J. M. Lim et al., "Breast cancer cell-derived soluble CD44 promotes tumor progression by triggering macrophage IL1β production," Cancer Research, vol. 80, pp. 1342–1356, 2020.

[87] S. Liu, J. S. Lee, C. Jie et al., "HER2 overexpression triggers an IL1α proinflammatory circuit to drive tumorigenesis and promote chemotherapy resistance," Cancer Research, vol. 78, pp. 2040–2051, 2018.

[88] R. Kolb, L. Phan, N. Borchering et al., "Obesity-associated NLRC4 inflammasome activation drives breast cancer progression," Nature Communications, vol. 7, p. 13007, 2016.

[89] Y. Wen, M. Wang, J. Yang et al., "A comparison of fentanyl and flurbiprofen axetil on serum VEGF-C, TNF-α, and IL-1β concentrations in women undergoing surgery for breast cancer," Pain Practice, vol. 15, pp. 530–537, 2015.

[90] K. Kersten, S. B. Coffelt, M. Hoogstraat et al., "Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages," Oncotimmunology, vol. 6, article e1334744, 2017.

[91] I. Kaplanov, Y. Carmi, R. Kornetsky et al., "Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation," Proceedings of the National Academy of Sciences, vol. 116, pp. 1361–1369, 2019.

[92] L. F. Campesato, A. P. M. Silva, L. Cordeiro et al., "High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity," Oncotarget, vol. 8, pp. 49470–49483, 2017.

[93] Z. Castaño, B. P. San Juan, A. Spiegel et al., "IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization," Nature Cell Biology, vol. 20, pp. 1084–1097, 2018.

[94] B. Fernandez-Garcia, N. Eiro, M. A. Miranda et al., "Prognostic significance of inflammatory factors expression by stroma from breast carcinomas," Carcinogenesis, vol. 37, pp. 768–776, 2016.

[95] M. Jeon, J. Han, S. J. Nam, J. E. Lee, and S. Kim, "Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone," Chemico-Biological Interactions, vol. 258, pp. 126–133, 2016.

[96] K. Tawara, H. Scott, J. Emathinger et al., "HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival: synergistic induction of IL-6 secretion by OSM and IL-1β," Oncotarget, vol. 10, pp. 2068–2085, 2019.

[97] B. Celtik, A. D. Yalcin, G. E. Genc, T. Bulut, S. Kuloglu Genc, and S. Gumuslu, “CXCL8, IL-1β and sCD200 are pro-inflammatory cytokines and their levels increase in the circulation of breast carcinoma patients,” Biomedical reports, vol. 5, pp. 259–263, 2016.

[98] R. W. Wyszynski, B. F. Gibbs, L. Varani, D. Iannotta, and V. V. Sumbayev, "Interleukin-1 beta induces the expression and production of stem cell factor by epithelial cells: crucial involvement of the PI-3K/mTOR pathway and HIF-1 transcription complex," Cellular & molecular immunology, vol. 13, pp. 47–56, 2016.

[99] I. Filippi, F. Carraro, and A. Naldi, "Interleukin-1β affects MDAMB231 breast cancer cell migration under hypoxia: role of HIF-1α and NFκB transcription factors," Mediators of Inflammation, vol. 2015, Article ID 789414, 10 pages, 2015.

[100] D. Ryan, A. Sinha, D. Bogan, J. Davies, J. Koziol, and W. M. ELShamy, "A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment," Oncotarget, vol. 8, pp. 103182–103206, 2017.

[101] P. Escobar, C. Bouchier, J. Serret et al., "IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production," Oncotarget, vol. 6, pp. 29034–29047, 2015.

[102] Y. Liubomirski, S. Lerrer, T. Meshel et al., "Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer," Frontiers in Immunology, vol. 10, p. 757, 2019.

[103] X. Luo, S. Huang, N. He et al., "Inflammatory human umbilical cord-derived mesenchymal stem cells promote stem cell-like characteristics of cancer cells in an IL-1β-dependent manner," BioMed Research International, vol. 2018, Article ID 7096707, 12 pages, 2018.

[104] M. D. Wellenstein, S. B. Coffelt, D. E. M. Duits et al., "Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis," Nature, vol. 572, pp. 538–542, 2019.

[105] L. Knoplová, E. Bigléri, N. Volodko et al., "Transcription factor c-Myb inhibits breast cancer lung metastasis by suppression of tumor cell seeding," Oncogene, vol. 37, pp. 1020–1030, 2018.

[106] R. Cheng, S. Billet, C. Liu et al., "Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells," Oncogene, vol. 39, pp. 1543–1556, 2020.

[107] B. Weichand, R. Popp, S. Dziumba et al., "S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β," The Journal of Experimental Medicine, vol. 214, pp. 2695–2713, 2017.

[108] S. J. Storr, S. Safuan, N. Ahmad, M. El-Refaee, A. M. Jackson, and S. G. Martin, "Macrophage-derived interleukin-1beta promotes human breast cancer cell migration and lymphatic adhesion in vitro," Cancer Immunology, Immunotherapy, vol. 66, pp. 1287–1294, 2017.

[109] E. A. Elghonaimy, S. A. Ibrahim, A. Youns et al., "Secretome of tumor-associated leukocytes augment epithelial-mesenchymal transition in positive lymph node breast cancer patients via activation of EGFR/Tyr 845 and NF-κB/65 signaling pathway," Tumour Biology, vol. 37, pp. 12441–12453, 2016.

[110] T. Vilsmaier, B. Rack, A. König et al., "Influence of circulating tumour cells on production of IL-1α, IL-1β and IL-12 in sera of
patients with primary diagnosis of breast cancer before treatment," Anticancer Research, vol. 36, pp. 5227–5236, 2016.

[111] W. Zhang, Y. Shen, H. Huang et al., "A Rosetta Stone for neutrophil in tumor microenvironment," Frontiers in Immunology, vol. 11, p. 1779, 2020.

[112] D. Lefley, F. Howard, F. Arshad et al., "Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts," Breast Cancer Research, vol. 21, p. 130, 2019.

[113] R. Eyre, D. G. Alférez, A. Santiago-Gómez et al., "Microenvironmental IL1β promotes breast cancer metastatic colonization in the bone via activation of Wnt signalling," Nature Communications, vol. 10, p. 5016, 2019.

[114] C. Tulotta, D. V. Lefley, K. Freeman et al., "Endogenous production of IL1β by breast cancer cells drives metastasis and colonization of the bone microenvironment," Clinical Cancer Research, vol. 25, pp. 2769–2782, 2019.

[115] R. G. Ungard, K. Linher-Melville, M. G. Nashed, M. Sharma, J. Wen, and G. Singh, "xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain," Molecular Pain, vol. 15, p. 1474880618822185, 2019.

[116] M. Pein, J. Insua-Rodriguez, T. Hongu et al., "Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs," Nature Communications, vol. 11, p. 1494, 2020.

[117] G. Bouchard, H. Therriault, R. Bujold, C. Saucier, and B. Paquette, "Induction of interleukin-1β by mouse mammary tumor irradiation promotes triple negative breast cancer cell invasion and metastasis development," International Journal of Radiation Biology, vol. 93, pp. 507–516, 2017.

[118] M. Dagenais, J. Dupaul-Chicoine, T. Douglas, C. Champagne, A. Morizot, and M. Saleh, "The interleukin (IL)-1RI pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis," Oncoimmunology, vol. 6, article e1287247, 2017.

[119] A. F. Navas, R. Mistry, S. Narayanan et al., "IL-1 induces p62/SQSTM1 and autophagy in ERα(+)/PR(+)/BCA cell lines concomitant with ERα and PR repression, conferring an ERα(-)/PR(-) BCA-like phenotype," Journal of cellular biochemistry, vol. 120, no. 2, pp. 1477–1491, 2019.

[120] A. M. Jiménez-Garduño, M. G. Mendoza-Rodríguez, D. Urrutia-Cabrera et al., "IL-1β-induced methylation of the estrogen receptor ERα gene correlates with EMT and chemoresistance in breast cancer cells," Biochemical and Biophysical Research Communications, vol. 490, pp. 780–785, 2017.

[121] M. Mendoza-Rodríguez, H. Arévalo Romero, E. M. Fuentes-Paná, J. T. Ayala-Sumuno, and I. Meza, "IL-1β induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells," Cancer Letters, vol. 390, pp. 39–44, 2017.

[122] M. G. Mendoza-Rodríguez, J. T. Ayala-Sumuno, L. García-Morales, H. Zamudio-Meza, E. A. Pérez-Yépez, and I. Meza, "IL-1β inflammatory cytokine-induced TP63 isoform ΔNp63α signaling cascade contributes to cisplatin resistance in human breast cancer cells," International Journal of Molecular Sciences, vol. 20, p. 270, 2019.

[123] K. Oh, O. Y. Lee, Y. Park, M. W. Seo, and D. S. Lee, "IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells," BMC Cancer, vol. 16, p. 724, 2016.

[124] S. I. Vastert, Y. Jamilloux, P. Quartier et al., "Anakinra in children and adults with Still’s disease," Rheumatology, vol. 58, pp. v9–v122, 2019.

[125] H. Ozdogan and S. Ugurlu, "Canakinumab for the treatment of familial Mediterranean fever," Expert Review of Clinical Immunology, vol. 13, pp. 393–404, 2017.

[126] M. F. McDermott, "Rilonacept in the treatment of chronic inflammatory disorders," Drugs Today (Barc), vol. 45, no. 6, pp. 423–430, 2009.

[127] A. Bettiol, E. Silvestri, G. Di Scala et al., "The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review," Rheumatology International, vol. 39, pp. 971–990, 2019.

[128] G. Cavalli and C. A. Dinarello, "Anakinra therapy for non-cancer inflammatory diseases," Frontiers in Pharmacology, vol. 9, p. 1157, 2018.

[129] P. M. Ridker, J. G. Mac Fadyen, T. Thuren, B. M. Everett, P. Libby, and R. J. Glynn, "Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial," Lancet, vol. 390, pp. 1833–1842, 2017.

[130] K. M. Schenk, J. E. Reuss, K. Choquette, and A. I. Spira, "A review of canakinumab and its therapeutic potential for non-small cell lung cancer," Anti-Cancer Drugs, vol. 30, pp. 879–885, 2019.

[131] A. Dhorepatil, S. Ball, R. K. Ghosh, M. Kondapaneni, and C. J. Lavie, "Canakinumab: promises and future in cardiometabolic diseases and malignancy," The American Journal of Medicine, vol. 132, pp. 312–324, 2019.

[132] Y. Peng and X. Wang, "Kinect protein solution survives ten years," Journal of Pharmaceutical and Biomedical Analysis, vol. 160, pp. 383–385, 2018.

[133] R. M. Fleischmann, H. Blddol, F. J. Blanco et al., "A phase II trial of lutikizumab, an anti-interleukin-1α/β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis," Arthritis & Rheumatology, vol. 71, pp. 1056–1069, 2019.

[134] C. A. Dinarello, "Treatment of inflammatory diseases with IL-1 blockade," Current oncolhinarlygology reports, vol. 6, pp. 1–14, 2018.

[135] R. Kurzrock, T. Hickish, L. Wyrwicz et al., "Interleukin-1 receptor antagonist levels predict favorable outcome after bemekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer," Oncoimmunology, vol. 8, article 1551651, 2019.

[136] C. F. Li, T. C. Chan, C. I. Wang et al., "RSF1 requires CEBP/β and hSNF2H to promote IL-1β-mediated angiogenesis: the clinical and therapeutic relevance of RSF1 overexpression and amplification in myxofibrosarcomas," Angiogenesis, vol. 24, pp. 533–548, 2021.

[137] N. Isambert, A. Hervieu, C. Rébé et al., "Fluorouracil and bevacinumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study," Oncoimmunology, vol. 7, article e1473419, 2018.

[138] I. Holen, D. V. Lefley, S. E. Francis et al., "IL-1 drives breast cancer growth and bone metastasis in vivo," Oncotarget, vol. 7, pp. 75571–75584, 2016.
[139] P. Zheng, Y. Zhang, B. Zhang, Y. Wang, Y. Wang, and L. Yang, "Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer," *Biomedicine & Pharmacotherapy*, vol. 107, pp. 1064–1073, 2018.

[140] C. A. Dinarello and J. W. van der Meer, "Treating inflammation by blocking interleukin-1 in humans," *Seminars in Immunology*, vol. 25, pp. 469–484, 2013.

[141] Y. Zhang, B. Xu, and X. P. Zhang, "Effects of miRNAs on functions of breast cancer stem cells and treatment of breast cancer," *Oncotargets and Therapy*, vol. 11, pp. 4263–4270, 2018.

[142] H. Akbulut, Y. E. Ersoy, E. Coskunpinar et al., "The role of miRNAs as a predictor of multicentricity in breast cancer," *Molecular Biology Reports*, vol. 46, pp. 1787–1796, 2019.

[143] J. P. Long, L. F. Dong, F. F. Chen, and Y. F. Fan, "miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells," *Oncology letters*, vol. 17, pp. 1573–1580, 2019.

[144] A. Caraffa, C. E. Gallenga, S. K. Kritas, G. Ronconi, P. Di Emidio, and P. Conti, "CAR-T cell therapy causes inflammation by IL-1 which activates inflammatory cytokine mast cells: anti-inflammatory role of IL-37," *Journal of Biological Regulators and Homeostatic Agents*, vol. 33, pp. 1981–1985, 2019.

[145] V. Gelfo, D. Romaniello, M. Mazzeschi et al., "Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies," *International Journal of Molecular Sciences*, vol. 21, p. 6009, 2020.

[146] V. Gelfo, M. Mazzeschi, G. Grilli et al., "A novel role for the interleukin-1 receptor axis in resistance to anti-EGFR therapy," *Cancers*, vol. 10, p. 355, 2018.

[147] M. Espinosa-Cotton, S. N. Rodman Iii, K. A. Ross et al., "Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma," *Journal for Immunotherapy of Cancer*, vol. 7, p. 79, 2019.

[148] E. Voronov and R. N. Apte, "Targeting the tumor microenvironment by intervention in interleukin-1 biology," *Current Pharmaceutical Design*, vol. 23, pp. 4893–4905, 2017.

[149] C. Woolston, "Breast cancer," *Nature*, vol. 527, p. S101, 2015.

[150] J. Shi, F. Liu, and Y. Song, "Progress: targeted therapy, immunotherapy, and new chemotherapy strategies in advanced triple-negative breast cancer," *Cancer Management and Research*, vol. 12, pp. 9375–9387, 2020.

[151] J. Jasionowska, M. Talarowska, E. Kalinka et al., "Interleukin 1 level, cognitive performance, and severity of depressive symptoms in patients treated with systemic anticancer therapy: a prospective study," *Croatian Medical Journal*, vol. 60, pp. 166–173, 2019.

[152] M. Z. Aumeeruddy and M. F. Mahomoodally, "Combating breast cancer using combination therapy with 3 phytochemicals: piperine, sulforaphane, and thymoquinone," *Cancer*, vol. 125, pp. 1600–1611, 2019.

[153] M. Du, Y. Ouyang, F. Meng et al., "Polymer-lipid hybrid nanoparticles: a novel drug delivery system for enhancing the activity of psoralen against breast cancer," *International Journal of Pharmaceutics*, vol. 561, pp. 274–282, 2019.